OUR PRODUCTS
Each capsule contains 5 mg chlordiazepoxide hydrochloride + 2.5 mg clidinium bromide
- Vivorax is contraindicated in the presence of glaucoma (as the anticholinergic component may produce a certain degree of mydriasis)
- In patients with prostatic hypertrophy and benign bladder neck obstruction.
- It is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide.
- In patients with breathing or urination problems.
- In cases of pregnancy and breastfeeding, as it causes birth defects in the fetus
- opioids
Concomitant use of benzodiazepines, including chlordiazepoxide hydrochloride, which is a component of Vivorax, and opioids increases the risk of respiratory depression due to actions at different receptor sites in the central nervous system that control breathing.
Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines are combined with opioids, the potential exists that benzodiazepines may exacerbate opioid-related respiratory depression.
- Oral anticoagulants:
Although clinical studies have not demonstrated a cause-and-effect relationship, clinicians should be aware that altered effects on blood clotting have rarely been reported in patients receiving oral anticoagulants and chlordiazepoxide hydrochloride, a component of Vivorax.
- Drug use and dependence:
Withdrawal symptoms, similar in nature to those observed with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), appeared after abrupt discontinuation of chlordiazepoxide. More severe withdrawal symptoms are usually limited to patients who have received excessive doses over a long period of time. Milder withdrawal symptoms (eg, anxiety, insomnia) have been reported after abrupt discontinuation of benzodiazepines continuously at therapeutic levels for several months. Thus, after extended treatment, abrupt discontinuation should generally be avoided and a gradual declining schedule of the dose should be followed. Addiction-prone individuals (eg drug addicts or alcoholics) should be closely monitored when receiving chlordiazepoxide or other psychotropic substances because of the predisposition of these patients to habituation and dependence
- Controlling emotional and physical factors in digestive disorders.
- As an adjuvant therapy in the treatment of peptic ulcers and in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.
- Chlordiazepoxide belongs to a class of medicines called benzodiazepines. It works by decreasing abnormal electrical activity in the brain. Clidinium belongs to a class of drugs called anticholinergics. Helps reduce stomach cramps and cramps
- Recommended dosage
Because of the varied individual responses to sedatives and anticholinergics, the optimal dose of Vivorax varies with the individual patient's diagnosis and response. Therefore, the dosage should be individualized to achieve the maximum possible beneficial effects. The usual dose is 1 or 2 capsules, 3 or 4 times a day before meals and before bed.
- Elderly :
The dose should be limited to the smallest effective amount to prevent the development of ataxia, excessive sedation, or confusion. The initial dose should not exceed 2 capsules per day, to be increased gradually as needed and tolerated. Elderly patients have an increased risk of dose-related adverse reactions.
When chlordiazepoxide hydrochloride was used alone, discontinuation of treatment was rare due to unwanted effects. Somnolence, ataxia, and confusion have been reported in some patients - especially the elderly and debilitated. While these effects can be avoided in almost all cases by appropriate dose adjustment, they have occasionally been observed in lower dose ranges. In a few cases syncope has been reported.
Other adverse reactions reported during treatment with chlordiazepoxide hydrochloride include isolated cases of skin rash, edema, slight menstrual irregularities, nausea and constipation, extrapyramidal symptoms, as well as increased and decreased sexual desire. These side effects are rare and are generally controlled by reducing the dose. Changes in EEG patterns (rapid low-voltage activity) have been observed in patients during and after treatment with chlordiazepoxide chloride.
Blood dyscrasias, including agranulocytosis, jaundice and hepatic impairment, have occasionally been reported during treatment with chlordiazepoxide hydrochloride. When treatment with chlordiazepoxide is prolonged, periodic blood counts and liver function tests are recommended.
The adverse effects reported with the use of Vivorax are those typical of anticholinergic symptoms, such as dry mouth, blurred vision, urinary frequency and constipation. Constipation occurs most often when Vyvorax is combined with other antispasmodic agents and/or a low-consumption diet
Vivorax (5mg/2.5mg) capsules........................... (590\2020)
A carton box containing two blisters, and each contains 10 capsules